Advances in Cancer Immunotherapyâ„¢ - Charlotte, NC

CME-certified regional program

Organizers

Asim Amin, MD, PhD – Levine Cancer Institute Carolinas Medical Center
John D. Powderly II, MD, CPI – Carolina BioOncology Institute, PLLC

Planning Committee

Asim Amin, MD, PhD – Levine Cancer Institute Carolinas Medical Center
Joseph W. Fay, MD – Baylor University Medical Center
Keith L. Knutson, PhD – Vaccine & Gene Therapy Institute of Florida
John D. Powderly II, MD, CPI – Carolina BioOncology Institute, PLLC
Brian I. Rini, MD – Cleveland Clinic Taussig Cancer Center
Alexander Spira, MD, PhD – Virginia Cancer Specialists

Purpose

Specifically designed for clinical oncologists and the entire medical team involved in treating cancer patients with immunotherapy, this introductory, CME-certified program provided an understanding of basic immunology principles in the clinical application and management of cancer immunotherapy and discussed emerging drugs and concepts in the cancer immunotherapy field.

Presented by leading authorities in tumor immunology and cancer immunotherapy, this program facilitated understanding of 1) the underlying principles of tumor immunology and immunotherapy, 2) the clinical indications for cancer immunotherapy and appropriate selection of patients, 3) patient management, and 4) the therapeutic effectiveness of immunotherapy to ultimately improve patient outcomes. 

Attendees also took advantage of the opportunity for professional networking that promotes collaboration and scientific exchange with experts, clinical oncologists and other health care providers from the surrounding community.

Intended Audience

The target audience for this program included clinical oncologists, those involved in patient care, early career individuals, allied health professionals, and patient advocates who wish to learn principles of tumor immunology and immunotherapy, as well as improve their ability to select patients for immunotherapy and provide state-of-the-art clinical management for their patients.

Session Topics

• Adoptive T Cell Therapy with Variations
• Antigen Presentation
• CTLA-4 Blockade: Indications and Clinical Management
• Cytokines (IL-2 and IFN): Indications and Clinical Management
• Immune Effector Mechanisms: B and T Cell Immunology
• Modulation of the Immune Response
• PD-1 Inhibition
• Principles of Immunotherapy
• Vaccines
• Vaccine Adjuvants

Educational Objectives

Upon completion of this program, the participants should have been able to:

• Interpret the key principles of tumor immunology and immunotherapy
• Analyze recent research and clinical applications of cytokines, cancer vaccines, T cell checkpoint inhibitors, adoptive immunotherapy and biomarkers
• Participate in scientific exchange with local colleagues, potential collaborators, and subject matter experts on research and clinical application of cancer immunotherapy
• Implement cancer immunotherapy treatments into clinical practice more effectively through a sound understanding of how they work, the clinical management of patients, and the potential to improve patient outcomes with tumor immunotherapy

Jointly provided by Clinical Immunology Society (CIS) and Society for Immunotherapy of Cancer (SITC)

The Advances of Cancer Immunotherapy^TM series is supported in part by educational grants from:

• AstraZeneca
• Bristol-Myers Squibb
• Dendreon
• Merck
• Prometheus

To view all of SITC’s supporters, please, click here.